AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway

BACKGROUND: Cisplatin is the first-line chemotherapy used against most upper aerodigestive tract carcinomas. In head and neck cancer, sensitivity to cisplatin remains the key issue in treatment response and outcome. Genetic heterogeneity and aberrant gene expression may be the intrinsic factors that...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Wei-Min, Chang, Yu-Chan, Yang, Yi-Chieh, Lin, Sze-Kwan, Chang, Peter Mu-Hsin, Hsiao, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558898/
https://www.ncbi.nlm.nih.gov/pubmed/31182137
http://dx.doi.org/10.1186/s13046-019-1256-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558898/
https://www.ncbi.nlm.nih.gov/pubmed/31182137
http://dx.doi.org/10.1186/s13046-019-1256-2

Ejemplares similares